{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:40:37Z","timestamp":1773308437363,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T00:00:00Z","timestamp":1153094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:p><jats:bold>Abstract\u2002<\/jats:bold> This double\u2010blind study was conducted to evaluate the efficacy and safety of gabapentin 1200\u2003mg\/day and 1800\u2003mg\/day (t.i.d.) compared to placebo as an adjunctive therapy in patients with refractory epilepsy. Patients were included when they had partial seizures at least eight times during a 12\u2010week baseline period despite treatment with one to two antiepileptic drugs. After baseline, eligible patients were randomized to gabapentin 1200\u2003mg\/day, 1800\u2003mg\/day, or placebo for 12\u2010week treatment. The primary end\u2010point, response ratio, was derived from seizure frequencies during treatment and baseline period based upon the seizure daily record by a patient. Of the 209 randomized patients, 86 received gabapentin 1200\u2003mg\/day, 41 received gabapentin 1800\u2003mg\/day, and 82 received placebo. A statistically significant difference was found between each of the two gabapentin groups and placebo for the primary efficacy end\u2010point, response ratio (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.005) with definite dose\u2013response (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). More gabapentin patients reported moderate to marked improvement in seizure frequency and intensity\/duration of each seizure than placebo patients. Treatment\u2010related adverse events were reported by approximately 65% of patients receiving gabapentin compared to approximately 46% of patients receiving placebo; somnolence and dizziness were the most common events. Gabapentin 1200\u2003mg\/day and 1800\u2003mg\/day significantly reduced the frequency of refractory seizures compared to placebo. Favorable tolerability of gabapentin was confirmed also in a Japanese population, consistent with previous global studies.<\/jats:p>","DOI":"10.1111\/j.1440-1819.2006.01553.x","type":"journal-article","created":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T13:14:11Z","timestamp":1153142051000},"page":"507-515","source":"Crossref","is-referenced-by-count":33,"title":["Treatment of partial seizures with gabapentin: Double\u2010blind, placebo\u2010controlled, parallel\u2010group study*"],"prefix":"10.1111","volume":"60","author":[{"given":"TOSHIO","family":"YAMAUCHI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SUNAO","family":"KANEKO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KAZUICHI","family":"YAGI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHINICHI","family":"SASE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,17]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb02586.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1991.tb04675.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507183130303"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91123-R"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2292"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02513.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1179\/016164101101199414"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00216-9"},{"key":"e_1_2_5_11_2","volume-title":"Encyclopedia of Biostatistics","author":"Hirotsu C","year":"1998"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.10.5768"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00084-3"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000123693.82339.FC"},{"key":"e_1_2_5_15_2","first-page":"S17","article-title":"Clinical pharmacokinetics of gabapentin","volume":"44","author":"McLean MJ","year":"1994","journal-title":"Neurology"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1006\/ebeh.2001.0283"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000123695.22623.32"},{"key":"e_1_2_5_18_2","unstructured":"Salas\u2010HumaraC WeintraubD BuchsbaumRet\u2003al.Comparative incidence of rash related to twelve antiepileptic drugs: results from the Columbia antiepileptic drug database. Program and Abstracts of the American Academy of Neurology 56th Annual Meeting San Francisco California Abstract S41.003 2004."},{"key":"e_1_2_5_19_2","unstructured":"WeintraubD BuchsbaumR SpencerHTet\u2003al.Psychiatric side effects of the newer antiepileptic drugs: results from the Columbia antiepileptic drug database. Program and Abstracts of the American Academy of Neurology 56th Annual Meeting San Francisco California Abstract P04.085 2004."}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1819.2006.01553.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1819.2006.01553.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T07:20:39Z","timestamp":1697268039000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1819.2006.01553.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,17]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1440-1819.2006.01553.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1819.2006.01553.x","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,17]]}}}